Sleep Disorders Clinical Trial
Official title:
Sleep Disturbance in Patients With End-Stage Renal Disease
Sleep disorders are common in patients who have chronic kidney disease (CKD). Insomnia is
reported in up to 50% of patients treated with hemodialysis compared to 12% of a control
population. Restless leg syndrome (RLS) and periodic limb movement disorder (PLM) have been
described in 30 to 70% of patients with end stage kidney disease (ESKD). Patients with CKD
have also been reported to have a very high prevalence of sleep apnoea disorder. Conventional
hemodialysis and peritoneal dialysis do not appear to improve sleep disorders in patients
with CKD. There is emerging evidence that nocturnal HD can lead to improvements in sleep
quality. Transplantation is thought to improve sleep-related disorders in some but not all
patients.
Project Aims
The aims of this project were three-fold:
1. To perform detailed assessment of sleep quality in a cohort of Irish patients with ESRD
2. To assess the feasability and tolerability of unattended home PSG and wrist actigraphy
as diagnostic tools in this cohort
3. To assess the impact of a change in RRT modality on sleep quality in Irish patients with
ESRD
Patients will not selected based on presence/absence of sleep disturbance. Patients will be
prioritized for recruitment if they were active on the transplant waitlist or a change in RRT
modality is planned.
Patients will be selected for inclusion if they were >16 years old, competent to
independently undertake the informed consent process and are currently on RRT or planned to
start RRT in the next three months. The following exclusion criteria will be applied:
dementia, active malignancy, major psychiatric disorder, home oxygen therapy, CPAP therapy,
and regular benzodiazepine use.
Baseline Evaluation
Baseline evaluation includes the following:
- Demographics and clinical parameters including medications and caffeine intake
- Dialysis prescription and adequacy (weekly standardised Kt/V)
- Laboratory data (haemoglobin, iron, phosphate, PTH)
- Subjective sleep quality as measured by Berlin Questionnaire, Epworth Sleepiness Scale,
Pittsburgh Sleep Quality Index and International Restless Leg Syndrome Questionnaire
- Quality of Life as assessed by the 36 Item Short Form Survey (SF-36), Beck Depression
Index and Centre for Epidemiologic Studies-Depression Scale
- Cognitive assessment as measured by Trail Making Tests 1 & 2, Category Fluency,
Controlled Oral Word Association Test and Hopkins Verbal Learning Test
- Unattended home polysomnography set-up up by investigator who was blinded to the results
of the above assessments
- Wrist actigraphy for 3-5 continuous days (Philips Respironics Actiwatch 2 System)
Follow-up Evaluation following RRT Modality Change Follow-up evaluation will be performed in
the same way as baseline evaluation at three - six months post switch of RRT modality. As the
impact of NHHD is of particular interest, follow-up evaluation will be performed at one and
six months post switch to NHHD in those patients who switched to NHHD. The follow-up home PSG
was performed on an 'on-dialysis' night and an 'off-dialysis' night to evaluate the impact of
the nocturnal procedure itself on sleep.
Data Analysis A sleep technician, blinded to the questionnaire results, compiles the PSG
analysis and reports in accordance with the American Academy of Sleep Medicine (AASM) manual
for the Scoring of Sleep and Associated Events (40). Actigraphy analysis is reported using
Philips Respironics Actiwatch Software.
Statistical methods Statistical analysis will be performed using Stata V14 and Prism V6. All
p values <0.05 will be considered statistically significant. Mean data and standard deviation
data will be analysed using independent samples t-test and repeated measures analysis of
variance (ANOVA). Nominal data will be analysed using chi-squared analysis.
Safety & Tolerability Reports were reviewed with a Respiratory Consultant with specialist
interest in Sleep Medicine on a regular basis and abnormal results were discussed in detail.
If specific therapy is indicated on the basis of the research tests, the treating
nephrologist will be informed and a management plan recommended.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02188498 -
Electrocardiography Data Analysis in Sleep Disorders
|
||
Completed |
NCT00990106 -
Augmentation Trial of Prazosin for Post-Traumatic Stress Disorder (PTSD)
|
N/A | |
Completed |
NCT00942253 -
Exercise Training in Dialysis Patients With Restless Legs Syndrome (RLS)
|
Phase 2 | |
Completed |
NCT00163670 -
The Impact of Sleep Disorders on Motor Vehicle Accidents
|
N/A | |
Completed |
NCT00203827 -
Pediatric Sleep Questionnaire: Use for Collection of Clinical Data
|
N/A | |
Completed |
NCT00256685 -
Study Evaluating DVS-233 SR to Treat Vasomotor Systems Associated With Menopause
|
Phase 3 | |
Completed |
NCT00174174 -
Provigil (Modafinil) Study by Taiwan Biotech Co.
|
N/A | |
Terminated |
NCT00750919 -
Twenty-six Week Extension Trial of Org 50081 (Esmirtazapine) in Outpatients With Chronic Primary Insomnia (176003/P05721/MK-8265-007)
|
Phase 3 | |
Completed |
NCT03075241 -
Z-Drugs for Sleep Disorders in Alzheimer's Disease
|
Phase 3 | |
Completed |
NCT02939586 -
The Effect of Haemodialysis in Sleep Apnoea
|
N/A | |
Completed |
NCT02585609 -
Sleep Quality in Patients With Advanced Cancer
|
N/A | |
Completed |
NCT03055156 -
Effect of High Rebound Mattress Toppers on Sleep and Sleep-Related Symptoms
|
N/A | |
Completed |
NCT02156128 -
Subjective Memory Complaints, Objective Memory Performance and Cognitive Training
|
N/A | |
Completed |
NCT01929447 -
Evaluation of WP200 With the Unified Probe (WP200U)
|
N/A | |
Completed |
NCT01906866 -
Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities
|
Phase 3 | |
Completed |
NCT01528462 -
Sleep Disorders Managed and Assessed Rapidly in Transient Ischemic Attack (TIA) and In Early Stroke
|
||
Completed |
NCT01220401 -
Efficacy of a Brief Nightmare Treatment for Veterans
|
N/A | |
Completed |
NCT01256983 -
Light for Renal Transplant Recipients Having a Sleep-Wake Dysregulation
|
Phase 0 | |
Not yet recruiting |
NCT00749814 -
Sleep Disturbances in Hospitalized Children
|
Phase 4 | |
Completed |
NCT00518986 -
Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression
|
Phase 4 |